Insperity's 60.4% three-month rally is backed by margin recovery, improving profits, strong liquidity and growth in the expanding PEO market.

Worksite employees declined as pricing discipline drove margin recovery.

CPAY's Q2 earnings and revenues beat estimates as Corporate Payments surge, margins expand and the 2026 profit guidance increases.

HR outsourcing provider Insperity (NYSE:NSP) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 1.7% year on year to $1.69 billion. Its non-GAAP profit of $0.34 per share was 6.9% above analysts’ consensus estimates.

Insperity (NSP) is back in focus after its second quarter 2026 earnings release, which showed modest sales growth, a return to quarterly profitability, fresh guidance, and new capital actions including share repurchases and a shelf registration. See our latest analysis for Insperity. Insperity's share price has climbed strongly this year, with a 77.39% 3 month share price return and a 31.05% year to date share price return, while the 5 year total shareholder return is still down 40.51%. If...

Shares of HR outsourcing provider Insperity (NYSE:NSP) fell 7.3% in the afternoon session after its second-quarter results and full-year guidance raised concerns about underlying business weakness.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Insperity's 2026 rally, earnings rebound and 4.4% yield support the case, but stretched valuation, high leverage and weak cash flow limit upside.

NSP is using pricing, HRScale, Workday and AI to revive growth as employee softness, benefits costs and competition pressure margins.

NSP beats on Q2 earnings as cost cuts and margin recovery lift the bottom line, but declining worksite employees and rising benefit costs pressure profitability.

Moby summary of Insperity, Inc.'s Q2 2026 earnings call

Insperity (NYSE:NSP) reported second-quarter 2026 adjusted earnings per share of $0.34 and adjusted EBITDA of $36 million, exceeding the midpoint of its projected ranges. Adjusted EPS rose 31% from a year earlier, while adjusted EBITDA increased 13%, as the professional employer organization continu

Adjusted EPS surges 31% year-over-year as HR Scale launch gains traction, but healthcare cost trends widen full-year EBITDA guidance.

Insperity (NSP) delivered earnings and revenue surprises of +3.03% and +0.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

HR outsourcing provider Insperity (NYSE:NSP) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.7% year on year to $1.69 billion. Its non-GAAP profit of $0.34 per share was 6.9% above analysts’ consensus estimates.

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.

HR outsourcing provider Insperity (NYSE:NSP) will be reporting results this Wednesday after the bell. Here’s what investors should know.

Insperity (NSP) is back on investors’ radar as attention turns to demand trends, cash flow considerations, and developments in its HR technology offerings, all of which are shaping views on the workforce management services provider. See our latest analysis for Insperity. Insperity’s recent 1 month share price return of 32.21% and 90 day share price return of 75.39% suggest momentum has strengthened, even though the 1 year total shareholder return is down 10.79% and longer term total...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.